Dermavant Presents New Data on Treatment of Patients with Skin of Color from ADORING 1 and 2 Phase 3 Pivotal Trials of VTAMA® (tapinarof) Cream, 1% in Adults and Children 2 Years of Age and Older with Atopic Dermatitis at the 2024 AAD Annual Meeting

LONG BEACH, Calif. & BASEL, Switzerland–(BUSINESS WIRE)–Dermavant Presents New Data on Patients with Skin of Color from ADORING 1 and 2 Trials of VTAMA® Cream, 1% in Atopic Dermatitis at AAD 2024
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks